What is the 13F Pro Quality Score for MCRB?

13F Pro ranks Seres Therapeutics, Inc. (MCRB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MCRB's current score at https://13fpro.ai/research/MCRB (free sign-up required for the full ranking).

Where does 13F Pro source MCRB data?

All Seres Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Seres Therapeutics, Inc. files with the SEC under CIK 1609809. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MCRB in?

Seres Therapeutics, Inc. (MCRB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MCRB research updated on 13F Pro?

MCRB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Seres Therapeutics, Inc.(MCRB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1609809 MCRB stock profile & AI dashboard →

13F Pro Quality Score

29.3/100

Rank #2,414 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

30.0/100

Profitability

30.0/100

Balance Sheet

42.0/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

8.7/100

Revenue Scale

30.0/100

Dilution Risk

0.6/100

MCRB Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Seres Therapeutics, Inc. (MCRB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MCRB at 29.3/100 on a 32-signal composite quality model, placing it at rank #2,414 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (8.7) and revenue growth (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Seres Therapeutics, Inc. reports quarterly revenue of $358.0K, net income of $-19.9M, free cash flow of $-16.4M. Top institutional holders of MCRB by reported 13-F value include Flagship Pioneering, VANGUARD CAPITAL MANAGEMENT, MARSHALL WACE, LLP, based on the most recent SEC filings. MCRB trades on the Nasdaq exchange and files with the SEC under CIK 1609809. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MCRB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Seres Therapeutics, Inc. directly from SEC EDGAR. Seres Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 7 and 46 since 2021, currently 29.3 — an improving long-term trajectory across 26 quarterly and live scoring snapshots.

Revenue

Q1 2026

$358.0K

Net Income

Q1 2026

$-19.9M

Free Cash Flow

Q1 2026

$-16.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$789.0KFY 2025

FY20 $33.2MFY21 $144.9MFY24 $0.00FY25 $789.0K

Net Income

+4088.2% YoY

$5.7MFY 2025

FY20 $-89.1MFY21 $-65.6MFY24 $136.0KFY25 $5.7M

Operating Income

+22.5% YoY

$-94.0MFY 2025

FY20 $-88.1MFY21 $-64.5MFY24 $-121.3MFY25 $-94.0M

EPS (Diluted)

$0.64FY 2025

FY20 $-0.06FY21 $-0.04FY24 $0.00FY25 $0.64

Total Assets

-1.2% YoY

$138.2MFY 2025

FY20 $342.9MFY21 $354.9MFY24 $139.8MFY25 $138.2M

Total Debt

—FY 2025

FY20 $25.0MFY21 $24.1MFY24 —FY25 —

Op. Cash Flow

+100.8% YoY

$1.1MFY 2025

FY20 $-93.6MFY21 $6.7MFY24 $-148.6MFY25 $1.1M

Metric	FY 2025	FY 2024	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$789.0K	$0.00 -100.0%	$144.9M +336.3%	$33.2M -3.7%	$34.5M +22.1%	$28.3M
Net Income	$5.7M +4088.2%	$136.0K +100.2%	$-65.6M +26.4%	$-89.1M -26.8%	$-70.3M +29.0%	$-98.9M
Operating Income	$-94.0M +22.5%	$-121.3M -88.1%	$-64.5M +26.8%	$-88.1M -22.6%	$-71.9M +28.3%	$-100.3M
EPS (Diluted)	$0.64	$0.00 +100.0%	$-0.04 +35.7%	$-0.06	—	—
Total Assets	$138.2M -1.2%	$139.8M -60.6%	$354.9M +3.5%	$342.9M +158.9%	$132.4M +9.9%	$120.5M
Total Debt	—	—	$24.1M -3.8%	$25.0M +0.0%	$25.0M	—
Operating Cash Flow	$1.1M +100.8%	$-148.6M -2322.0%	$6.7M +107.1%	$-93.6M -22.3%	$-76.5M -21.7%	$-62.9M

AI Insight: MCRB Ratio Trends

MCRB's return data is almost entirely missing, but ROA swings from +79.6% in Q1 2025 to -67.7% in Q1 2026, signaling extreme earnings volatility.

• ROA swung violently: +79.6% in Q1 2025, then -55.2% in Q2 2025, -44.4% in Q4 2025, and -67.7% in Q1 2026.

• ROE turned sharply negative at -138.7% in Q4 2025, after a brief positive reading of 75.1% in Q3 2025.

• Most profitability metrics — OpMargin, NPM, ROIC, D/E — are absent across all periods, limiting trend visibility.

⚠ TTM ROA stands at -39.9% and ROE at -177.0%, suggesting persistent losses are eroding equity rapidly.

⚠ The isolated Q1 2025 ROA spike of +79.6% warrants scrutiny — likely a one-off item distorting the series.

Get alerted when MCRB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Seres Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MCRB

Flagship Pioneering Inc.
$10.3M1,155,850 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.6M294,143 sh
MARSHALL WACE, LLP
$1.2M139,539 sh
Vontobel Holding Ltd.
$1.2M138,468 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$934.4K105,339 sh
BlackRock, Inc.
$905.0K102,026 sh
GEODE CAPITAL MANAGEMENT, LLC
$664.1K74,835 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$575.7K64,900 sh
AMERICAN CENTURY COMPANIES INC
$552.7K62,316 sh
CITADEL ADVISORS LLC
$527.8K59,500 sh

Fund	Value	Shares
Flagship Pioneering Inc.	$10.3M	1,155,850
VANGUARD CAPITAL MANAGEMENT LLC	$2.6M	294,143
MARSHALL WACE, LLP	$1.2M	139,539
Vontobel Holding Ltd.	$1.2M	138,468
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$934.4K	105,339
BlackRock, Inc.	$905.0K	102,026
GEODE CAPITAL MANAGEMENT, LLC	$664.1K	74,835
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$575.7K	64,900
AMERICAN CENTURY COMPANIES INC	$552.7K	62,316
CITADEL ADVISORS LLC	$527.8K	59,500

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MCRB on your watchlist

Track score changes the day Seres Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MCRB a good stock to buy?

13F Pro's AI-powered analysis of Seres Therapeutics, Inc. (MCRB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MCRB are available on the MCRB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MCRB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MCRB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Seres Therapeutics, Inc.'s investment landscape.